Stephen Kearney 🇺🇦🇮🇪

Curious, medic (oncology)

[NEJM AI @NEJM_AI]

A new editorial discusses whether clinical genetics is prepared for a world in which patients and families can generate rare disease analyses on their own. Full editorial: https://t.co/8Dr2ylaziO

[International Society of Liquid Biopsy @isliquidbiopsy]

🎯We are incredibly proud to announce that the Journal of Liquid Biopsy has been awarded its first Impact Factor of 5.0!

💣This exciting achievement is the result of the dedication, commitment, and excellence of our entire community.

❤️We are deeply grateful to all the authors, reviewers, the Editor-in-Chief, the Honorary Editor, and every member of the Editorial Board, whose hard work and unwavering commitment have established the Journal of Liquid Biopsy as a leading journal in the field.

🙏🏼Thank you to everyone who made this remarkable milestone possible.

🩸This is only the beginning. Together, we will continue to raise the bar, advance scientific excellence, and shape the future of liquid biopsy.

The best is yet to come! 🚀
@UmbertoMalapel1 @ChristianRolfo @drgandara @olakhorshid Jacob Berchuck @aadel_chaudhuri @CtcLaboratory Nicola Fusco Joe Ibrahim, Ph.D. @ElJanLe Natasha Leighl @BrunaPellini Francesco Pepe @LuisERaez1 @Al3ssandroRusso @RobertoBoreaMD @MJOSESERRANO19 @DrYukselUrun @ErulEnes @ReduzziCarol @ddemiguelperez @PasqualePisapia @ESaldanhaMD @eleonora_nicolo @DrMirallas

[Journal of Clinical Oncology @JCO_ASCO]

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

Read the full article. https://t.co/TLiHhowLV5

[Nature Reviews Cancer @NatureRevCancer]

Our JULY issue is now live!🌞 🏖️🍉

It features #REVIEWS on:
- AI for integrating cancer multi-omics & clinical data
- Targeting cancer dormancy
- Context-dependent synthetic lethality
- Microbiota in immune-related adverse events

📖 👇
https://t.co/iI7yvbUBfU

[Niko McCarty. @NikoMcCarty]

I think biotechnology is the most exciting thing you can work on. But I have never written down my reasons for thinking this explicitly, so here are some bulleted arguments:

- It is incredibly broad across both space and time.

Biology spans every possible scale, from atoms to organisms to the planet. Biochemical reactions happen at nanosecond timescales, whereas organisms evolve over hours (in some cases) or millennia. This breadth means that there is always something new to discover. I believe it's possible for any undergraduate student, with a little bit of guidance, to make an original discovery in a matter of weeks. It may not be an important discovery, but you can quickly find things that nobody else has ever found before.

- Insights gained into one organism apply to many others.

It is a miracle that we can engineer living organisms at all. How peculiar that a bacterial defense system (CRISPR-Cas) can be adapted into a gene-editing tool which works not only in bacteria, but also in plants and algae and humans. All life shares a common ancestor, and is assembled from a common set of ingredients, so we can mix-and-match our tools to solve incredibly diverse problems. (If life formed multiple times, and each "tree" of life persisted to the present, then the tools made for one branch of that tree would be unlikely to work in another. Fortunately, this is not the case.)

- A deep understanding of biology can be applied to a *huge* range of problems.

Say you're a protein designer, using computers to design new types of molecules. Such a skill is not only useful for making medicines! It can also be used to make antivenoms, or to design peptides that protect plants against pests, or a million other things. This means that, as a biotechnologist, you can work on medicines or climate change or agriculture or making life multiplanetary ... all using a common set of skills.

It is just unfortunate that biology is taught in such a boring way in schools, with textbooks and rote memorization. My advice would be to fight through your boredom and then join a research laboratory, as soon as you possibly can. Get hands-on skills and try to work on your own problems.

[Endpoints News @endpts]

Endpoints News is 10. Founders @arsalanarif and @JohnCendpts reflect on launching broke with no investors, a 50/50 split everyone warned against, and the road from bootstrapped startup to the @FinancialTimes. https://t.co/oytcV0bkph

[Dr Rishabh Jain @DrRishabhOnco]

A question for fellow oncologists:

What is the highest number of distinct primary cancers you’ve encountered in a single patient?

My record is 3:

🟢 RCC
🔵 Prostate cancer
🟠 Rectal cancer

Cases like these are a reminder of how complex cancer biology can be.

What’s yours?

[CancerNetwork® @CancerNetwrk]

🚨 A new top 5 articles has dropped 🚨

1. https://t.co/XC6SiAixT5
2. https://t.co/3PHX994zIQ
3. https://t.co/OjvPJXN9zz
4. https://t.co/b15HSbXHNR
5. https://t.co/QF2BO5eT2f

#pancsm #lcsm #bcsm #RadOnc #pcsm #oncology

[AppliedRadiology @Applied_Rad]

Case Report: Combination Therapy Improves Efficacy in Widespread Prostate Metastatic Disease

🔗 Full case details here: https://t.co/VU8zhzqzFE

A 79-year-old man with prostate cancer previously treated in 1997 with radical prostatectomy and subsequently treated with hormone therapy (ADT, abiraterone), chemotherapy (docetaxel, cabazitaxel), and strontium for metastatic bone disease presented in July 2017 with rising PSA levels.

#MensHealthMonth #MHM26 #CaseStudy #RadOncEd #MedEd

[Waggoner Lab @LabWaggoner]

Review on NK cell-based immunotherapy
https://t.co/Mz8XbUgZZP

[Radiology @radiology_rsna]

Drs. @XinyiTang_WCH, Yang, and colleagues developed an AI-based tool that improves image acquisition in standard planes and imaging efficiency among junior novice practitioners of dynamic wrist-hand US. @IHuaXi https://t.co/1cUNZr02tX

[European Society of Human Genetics (ESHG) @eshgsociety]

🧬 New ACMG statement on reporting VUS in germline genetic and genomic testing.

Key points: phenotype-relevant VUS in symptomatic individuals, VUS subclasses, follow-up recommendations, reclassification updates, data sharing & collaboration.

https://t.co/84AFrqpVSK

[Eric Topol @EricTopol]

Here's a summary of the 4 natural experiments which all report ~20% reduction of dementia
https://t.co/GQ5apkwgB7

[Anirban Maitra @Aiims1742]

A @NEJM review on Diagnosis of #PancreaticCancer 80 years ago (1946) highlights many of the challenges of early detection & later presentation that persists till present day. Interesting that the relationship to diabetes/hyperglycemia was noted even then.
https://t.co/58PFP0S2at

[Anirban Maitra @Aiims1742]

Congratulations @CNuevoTapioles & Mark Philips @nyugrossman @Perlmutter_CC
Beautiful work in @CellReports showing the mechanistic underpinning of how KRAS upregulates glycolysis.
https://t.co/q3YYWmHQrQ

[Zeke Emanuel @ZekeEmanuel]

Clinical AI by 2030 is coming. But fee-for-service reimbursement will make it expensive theater. Value-based payment makes it real.

I discussed this and more with Kevin O'Leary and Martin Cech of @healthtechnerds below.

[Oncology Times @OncologyTimes]

"92% of #oncologists report that if their patients knew about #MRDtesting as an option, they would be interested in incorporating it into their #cancer management and monitoring plans," reports Yuri Fesko, MD, Senior Vice President and Chief Medical Officer for Quest Diagnostics.

[Evis Drenova @evisdrenova]

One fascinating consequence of GLP-1s/Ozempic:

For decades, people said that big pharma would never release actually effective obesity drugs because they’d lose too much money from downstream chronic disease treatment.

We’re seeing almost the exact opposite.

[OncoAlert @OncoAlert]

The OncoAlert🚨 GU faculty’s TOP 10 abstracts In GU Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior GU cancer experts across #ProstateCancer #KidneyCancer #BladderCancer .
A snapshot of what will shape GU oncology at #ASCO26 👇

1️⃣ LBA5007 — TALAPRO-3
Talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC with HRR alterations

2️⃣ LBA1 — PROTEUS
Perioperative apalutamide + ADT vs ADT in high-risk localized/locally advanced prostate cancer (final Phase 3)

3️⃣ 5001 — ENZAMET genomic analysis
Decipher >0.85 to identify benefit from adding docetaxel to ADT + enzalutamide

4️⃣ LBA4511 — KEYNOTE-564 ctDNA
ctDNA dynamics in RCC treated with adjuvant pembrolizumab vs placebo

5️⃣ 4502 — RAMPART
Durvalumab vs active monitoring after resection in RCC (Phase 3 RCT)

6️⃣ 4500 — RADICAL (A031801)
Radium-223 + cabozantinib in RCC with bone metastases

7️⃣ 4507 — EV-302 long-term follow-up
Enfortumab vedotin + pembrolizumab vs chemotherapy in 1L LA/mUC

8️⃣ 4513 — AMBASSADOR (A031501)
HRQoL with adjuvant pembrolizumab vs observation in high-risk MIBC

9️⃣ 4503 — SAKK 06/19
Perioperative intravesical rBCG + chemo-IO strategy in MIBC (primary analysis)

🔟 4510 — KEYNOTE-905
HRQoL with perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible MIBC

Leads
@nataliagandur
@scocmem
@AmandaNizamMD
@WeOncologists

Senior Faculty
@montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @Silke_Gillessen
@tompowles1 @AndreaNecchi @cdanicas @AOmlin

Pinging
@crisbergerot @HHammersMD @ravikanesvaran @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @brian_rini

[François Chollet @fchollet]

Thinking of AI as a productivity booster for prior workflows is the wrong framing. Like all of the previous waves of computerization/softwarization, AI is a tool that lets you do new things in new ways.